Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1047025

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many times he has used his powers under the Health Service Medical Supplies (Costs) Act 2017 to impose lower prices on unbranded generic or off-patent medicines sold to the NHS; and how many companies have had lowered prices as a result of those powers.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211794
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>The Department has not used its powers under the NHS Act 2006, as amended by the Health Service Medical Supplies (Costs) Act 2017, to limit prices of generic medicines. The Department continues to work with the Competition and Markets Authority on the cases they are taking forward. It has also put in place the Health Service Products (Provision and Disclosure of Information) Regulations 2018 that support its price setting powers. It is currently preparing a consultation with industry representative bodies on proposals for implementation of the price setting powers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:20:24 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047027

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the NHS' spend on unbranded generic or off-patent medicines has reduced since the Health Service Medical Supplies (Costs) Act 2017 came into force.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211795
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>Spend on generic medicines in primary care went down by 4% in 2017/18 compared to 2016/17 whilst the number of items dispensed remained broadly stable.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:21:03 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

1047114

registered interest
date	23/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an (a) assessment of the equity of the level of remuneration for special medicinal products sold to the NHS and (b) estimate of what is an equitable amount of remuneration; and if he will make a statement.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	211797
answer	answer is ministerial correction date of answer 28/01/2019 answer text <p>In the period from December 2017 to November 2018, the Department spent £65 million on specials in primary care in England. That is 0.7% of spend on medicines in primary care. Spend on specials has reduced significantly since 2010 when it was £136 million. This is the consequence of a reduction in the prescribing of specials and the introduction of reimbursement prices for the most commonly prescribed specials. Specials listed with a price in the Drug Tariff incentivise community pharmacies to source the special at the lowest price possible which creates a competitive market and reduces costs. Out of the £65 million spent on specials in 2018, £20 million was spent on specials listed with a price in the Drug Tariff covering more than half of the items dispensed. The Department aims to include more specials with a reimbursement price in the Drug Tariff and seek alternative arrangements for specials that are not commonly prescribed and therefore cannot be listed with a reimbursement price. Potential savings will depend on the specials which can be listed with a Drug Tariff reimbursement price and the approach taken for those which cannot.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/01/2019 17:22:39 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

947297

registered interest
date	24/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS in England of special medicinal products over the last 12 months.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167951
answer	answer is ministerial correction date of answer 05/09/2018 answer text <p>In the most recent 12 month period for which data is available (June 2017 to May 2018) the cost of National Health Service special medicinal products dispensed in the community in England was £70.5 million down from £135.5 million in 2010.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/09/2018 10:25:43 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford

947011

registered interest
date	23/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has undertaken an impact assessment on the potential beneficial effects of regulating the dispensing of special medicinal products in England.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	167294
answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>We have made no such assessment. The supply of special medicinal products is regulated in the United Kingdom by the Human Medicines Regulations 2012. In addition, in England, NHS dispensing by pharmacies is regulated by the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:00:47 answering member 4067 label Biography information for Steve Brine
tabling member	4385 label Biography information for Dr Philippa Whitford